Literature DB >> 18521585

Pharmacokinetic-pharmacodynamic modeling of the influence of chronic phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery.

Juan Fernández-Candil1, Pedro L Gambús, Iñaki F Trocóniz, Ricard Valero, Enrique Carrero, Lorea Bueno, Neus Fábregas.   

Abstract

BACKGROUND: Antiepileptic drugs decrease the intensity of the effect of neuromuscular blocking agents. The objective of this study was to evaluate the influence of chronic phenytoin therapy (CPT) on the pharmacokinetics (PK) and pharmacodynamics (PD) of rocuronium.
METHODS: A total of 21 patients undergoing intracranial surgery were enrolled in the study. Ten of these were under CPT. Rocuronium was administered intravenously. Arterial blood samples were drawn, and the T1% (percentage change from the response to the supramaximal stimulus) derived from electromyogram was continuously recorded. NONMEM: software was used to construct, evaluate and validate the PKPD models.
RESULTS: The PKPD of rocuronium was described using a three-compartment PK model and effect compartment model. The CPT therapy was found to increase the total plasma clearance from 0.26 to 0.75 L min(-1). The PD model parameter estimates were k(e0)= 0.073 min(-1), IC(50) (the steady-state plasma concentration eliciting half of the maximum response) = 836 ng mL(-1) and gamma = 3.13.
CONCLUSIONS: Chronic phenytoin therapy increases the clearance of rocuronium from 0.26 to 0.75 L min(-1) but has no effect on the k(e0), IC(50) or gamma parameters.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18521585     DOI: 10.1007/s00228-008-0485-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  33 in total

Review 1.  Neuromuscular blocking drugs for the new millennium: current practice, future trends--comparative pharmacology of neuromuscular blocking drugs.

Authors:  F Donati
Journal:  Anesth Analg       Date:  2000-05       Impact factor: 5.108

Review 2.  Pharmacokinetic studies of neuromuscular blocking agents: good clinical research practice (GCRP).

Authors:  J Viby-Mogensen; D Ostergaard; F Donati; D Fisher; J Hunter; J P Kampmann; A Kopman; J H Proost; S N Rasmussen; L T Skovgaard; F Varin; P M Wright
Journal:  Acta Anaesthesiol Scand       Date:  2000-11       Impact factor: 2.105

3.  The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis.

Authors:  M M van Miert; N B Eastwood; A H Boyd; C J Parker; J M Hunter
Journal:  Br J Clin Pharmacol       Date:  1997-08       Impact factor: 4.335

4.  Parallel induction of plasma alpha 1-acid glycoprotein concentration and antipyrine clearance by drugs.

Authors:  F P Abramson
Journal:  Prog Clin Biol Res       Date:  1989

5.  Resistance to pancuronium in patients receiving carbamazepine.

Authors:  S Roth; Z Y Ebrahim
Journal:  Anesthesiology       Date:  1987-05       Impact factor: 7.892

6.  Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy.

Authors:  S G Soriano; L J Sullivan; K Venkatakrishnan; D J Greenblatt; J A Martyn
Journal:  Br J Anaesth       Date:  2001-02       Impact factor: 9.166

7.  Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient.

Authors:  L Bergeron; D R Bevan; A Berrill; R Kahwaji; F Varin
Journal:  Anesthesiology       Date:  2001-08       Impact factor: 7.892

8.  Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development.

Authors:  C F Minto; T W Schnider; T D Egan; E Youngs; H J Lemmens; P L Gambus; V Billard; J F Hoke; K H Moore; D J Hermann; K T Muir; J W Mandema; S L Shafer
Journal:  Anesthesiology       Date:  1997-01       Impact factor: 7.892

9.  Changes in the concentration of serum alpha 1-acid glycoprotein in epileptic patients.

Authors:  K Morita; A Yamaji
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

10.  Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients.

Authors:  K Alloul; D G Whalley; F Shutway; Z Ebrahim; F Varin
Journal:  Anesthesiology       Date:  1996-02       Impact factor: 7.892

View more
  3 in total

Review 1.  Pharmacokinetic-pharmacodynamic modelling in anaesthesia.

Authors:  Pedro L Gambús; Iñaki F Trocóniz
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

2.  Influence of real-time Bayesian forecasting of pharmacokinetic parameters on the precision of a rocuronium target-controlled infusion.

Authors:  Cyrus Motamed; Jean-Michel Devys; Bertrand Debaene; Valérie Billard
Journal:  Eur J Clin Pharmacol       Date:  2012-02-19       Impact factor: 2.953

3.  Synergism between rocuronium and cisatracurium: comparison of the Minto and Greco interaction models.

Authors:  Soeun Jeon; Jae Young Kwon; Hae-Kyu Kim; Tae Kyun Kim
Journal:  Korean J Anesthesiol       Date:  2016-06-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.